GLP-1 Receptor Agonists and Healthy Aging: From Diabetes Therapy to Longevity Medicine

1. Introduction: From a Gut Hormone to a Test of Longevity Medicine

Glucagon-like peptide-1 (GLP-1) receptor agonists are the first widely prescribed drugs to produce sustained, double-digit percentage weight loss and a demonstrated reduction in hard cardiovascular endpoints in people without diabetes. Semaglutide, liraglutide, dulaglutide, and the dual GIP/GLP-1 agonist tirzepatide were engineered for type 2 diabetes, repurposed for obesity, and are now tested against the diseases that dominate late-life mortality: atherosclerotic cardiovascular disease, chronic kidney disease, metabolic liver disease, and neurodegeneration. For geroscience the question is specific and stringent: do these drugs treat individual age-related diseases in parallel, or do they modulate aging biology itself in a way that extends healthy lifespan beyond the sum of those disease effects?

This review distinguishes what randomised trials have proven, what mechanistic studies make plausible, and what remains speculative, including the negative 2025 data that narrowed the neuroprotection hypothesis.

2. The Incretin System: Physiology and Pharmacology

2.1. Native GLP-1 Biology

GLP-1(7-36) amide is secreted postprandially by enteroendocrine L-cells of the distal intestine and colon, with smaller contributions from preproglucagon-expressing neurons in the nucleus tractus solitarius. Its half-life is 1-2 minutes due to cleavage by dipeptidyl peptidase-4 (DPP-4) and renal clearance. In its brief circulation it acts in a glucose-dependent manner: it augments insulin secretion only when glucose is elevated, suppresses glucagon, slows gastric emptying via vagal afferents, and reduces appetite through central GLP-1 receptors. This glucose dependence explains the low intrinsic hypoglycaemia risk compared with sulfonylureas or insulin.

GLP-1 receptors are G-protein-coupled receptors expressed far beyond pancreatic beta-cells: in the hypothalamus (arcuate, paraventricular nuclei), hindbrain (area postrema, nucleus tractus solitarius), heart, vascular endothelium, kidney, liver, lung, and on subsets of immune cells. Peripheral signals reach the brain both via circumventricular organs with fenestrated capillaries and via vagal sensory afferents. This broad distribution underlies effects that cannot be explained by weight loss alone.

2.2. From Short-Acting Peptides to Multi-Agonists

The therapeutic advance was not discovery of the pathway but its pharmacological stabilisation. Chemical modifications — albumin binding, fatty-acid acylation, DPP-4 resistance, and fusion to engineered backbones — extended half-life from minutes to days to a week, enabling stable receptor occupation without continuous infusion.

*Weight change versus baseline in adults with overweight or obesity without diabetes at the highest approved or studied dose; diabetes trials show smaller absolute loss. Table summarises class evolution; individual trial populations differ and are not directly comparable without head-to-head data.

3. Clinical Evidence: What Randomised Trials Have Proven

3.1. Diabetes Cardiovascular Outcome Trials — the Foundation

Before obesity trials, cardiovascular outcome trials (CVOTs) mandated by regulators in type 2 diabetes established that GLP-1 agonists reduce major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). LEADER (liraglutide, n=9,340, HR 0.87), SUSTAIN-6 (semaglutide s.c., HR 0.74), REWIND (dulaglutide, n=9,901, HR 0.88), and Harmony (albiglutide) each showed 12-26% relative reductions in MACE in high-risk diabetes populations, with benefits driven largely by stroke and with accompanying reductions in albuminuria progression. These results were confined to diabetes and were not longevity claims, but they provided the first hard-outcome signal that incretin activation alters vascular aging trajectories.

3.2. Obesity Without Diabetes: STEP and SURMOUNT

The STEP programme redefined pharmacological weight loss. In STEP 1 (n=1,961, BMI ≥30 or ≥27 with comorbidity, without diabetes), once-weekly semaglutide 2.4 mg produced a mean change of −14.9% versus −2.4% with placebo at 68 weeks, with 69% of participants losing ≥10% and 32% losing ≥20% of body weight. Parallel trials (STEP 2 in diabetes, STEP 5 at 104 weeks, STEP 8 versus liraglutide) confirmed durability to two years while on treatment and substantially greater loss than previous agents. SURMOUNT-1 (n=2,539, tirzepatide) subsequently showed −15.0%, −19.5%, and −20.9% at 5, 10, and 15 mg versus −3.1% placebo at 72 weeks, with glycaemic, blood pressure, lipid, and liver-fat improvements correlating with weight loss magnitude. Critically, withdrawal studies show rapid regain — approximately two-thirds of lost weight regained within one year off drug — implying chronic therapy if benefits are to be maintained.

3.3. Hard Cardiovascular Endpoints Without Diabetes: SELECT

SELECT (n=17,604, BMI ≥27 with established atherosclerotic cardiovascular disease, no diabetes, median follow-up ~40 months) tested whether the CVOT signal extends beyond diabetes and beyond glucose lowering. Semaglutide 2.4 mg weekly reduced the primary MACE composite by 20% (HR 0.80, 95% CI 0.72-0.90; 6.5% vs 8.0% events), with consistent effects across BMI strata and a 19% reduction in all-cause mortality (HR 0.81). Absolute risk reduction was 1.5 percentage points over ~3.3 years. For geroscience, SELECT is the first large trial to show that an incretin drug reduces the leading cause of late-life death in overweight individuals without diabetes — an indirect but genuine extension of life expectancy for the treated high-risk group. It did not measure biological aging rate, epigenetic clocks, or maximum lifespan.

3.4. Kidney Outcomes: FLOW

FLOW (n=3,533, type 2 diabetes with chronic kidney disease, eGFR 50-75 and albuminuria or eGFR 25-50 with albuminuria), stopped early for efficacy in 2024, reported a 24% reduction in the primary composite of kidney failure, ≥50% eGFR decline, or kidney or cardiovascular death (HR 0.76) and a 20% reduction in all-cause mortality with weekly semaglutide 1.0 mg. Slower eGFR decline and reduced albuminuria were observed. The kidney — a vascular organ whose filtration loss tracks biological age — provides the second hard-organ longevity signal beyond the heart. Dedicated trials in non-diabetic CKD with GLP-1 therapy are ongoing; current renal claims beyond diabetic CKD remain investigational.

4. Mechanisms Potentially Relevant to Aging: Evidence and Boundaries

The following mechanisms are ordered by strength of human evidence, not by narrative appeal. Table 2 summarises the grading used throughout this section.

4.1. Adiposity, Ectopic Fat, and Mechanical Load — Confirmed

Visceral and ectopic fat (liver, muscle, pericardium) drives insulin resistance, atherogenesis, and musculoskeletal disability. Weight loss of 10-20% reduces liver steatosis, blood pressure, triglycerides, glycated haemoglobin, sleep apnoea severity, and knee pain — each a determinant of late-life disability and mortality. In SELECT, benefit was observed across baseline BMI, indicating contributions beyond weight magnitude alone, but weight loss remains the dominant mediator and the most parsimonious explanation for much of the observed risk reduction.

4.2. Chronic Low-Grade Inflammation — Plausible with Confirmed Biomarker Signal

Aging is characterised by sterile, low-grade inflammation (inflammaging) driven by adipose-derived cytokines, NLRP3 inflammasome activation, and senescence-associated secretory phenotype (SASP) mediators. In STEP, SELECT, and FLOW, GLP-1 therapy lowered high-sensitivity C-reactive protein (hsCRP) by 30-40% and reduced IL-6 and circulating leukocyte counts. In human adipose and circulating monocytes, GLP-1 receptor signalling is associated with M2 macrophage polarisation, suppressed NF-κB activation, and lower SASP factor release. Whether this reflects direct immune signalling or is secondary to fat loss cannot be fully separated in humans; rodent data support both pathways. No trial has shown that this anti-inflammatory signature slows a validated aging biomarker independently of weight.

4.3. Vascular, Cardiac, and Renal Protection — Confirmed for Cardiorenal Endpoints

GLP-1 receptors on endothelial and smooth-muscle cells, cardiomyocytes, and renal podocytes and tubules provide a plausible direct vascular axis. Trials show reduced albuminuria, slower eGFR decline, improved blood pressure modestly (~3-5 mmHg), and signals for improved endothelial function and plaque stability on imaging. Epicardial fat reduction and natriuresis contribute. Importantly, SELECT demonstrated outcome reduction in patients already receiving statins, antihypertensives, and antithrombotics, indicating incremental benefit above standard vascular prevention — the profile expected of a drug acting on residual inflammatory-metabolic risk.

4.4. Brain Aging and Neurodegeneration — Preclinical Promise, Human Failure to Date

GLP-1 receptors are abundant in hippocampus, cortex, and substantia nigra. In mouse models of Alzheimer’s and Parkinson’s disease, GLP-1 agonists reduce microglial activation, lower Aβ and α-synuclein aggregation, improve synaptic plasticity, and attenuate neuronal loss, often at exposures exceeding human therapeutic levels and with variable blood-brain barrier penetration (semaglutide crosses poorly; exenatide and liraglutide more measurably). Early small trials and Danish registry analyses suggested lower dementia incidence among GLP-1 users.

The EVOKE and EVOKE+ phase 3 trials (oral semaglutide 14 mg in early symptomatic Alzheimer’s, n≈1,855 each, 156 weeks) reported in 2025 no slowing of cognitive or functional decline versus placebo on the Clinical Dementia Rating — Sum of Boxes, despite signals on certain Alzheimer’s plasma biomarkers. Extension phases were discontinued. A small phase 2 trial of liraglutide (ELAD, n=204) reported no clear cognitive benefit. For aging medicine this is a decisive correction: the anti-inflammatory and metabolic effects of incretins do not automatically confer clinical neuroprotection, and claims of cognitive rejuvenation must be regarded as not confirmed. Trials in Parkinson’s disease (exenatide, lixisenatide) remain phase 2 and hypothesis-generating.

4.5. Nutrient-Sensing and Energy Homeostasis — Partial, Indirect

GLP-1 therapy restores aspects of deregulated nutrient sensing — improved insulin sensitivity, lower fasting glucagon, reduced hepatic de novo lipogenesis — but does not directly inhibit mTOR, activate AMPK in the manner of caloric restriction mimetics, or induce autophagy as a primary mechanism. No human data show reduced telomere attrition, enhanced DNA repair, or clearance of senescent cells. One-year studies of epigenetic clocks (e.g., DunedinPACE) during substantial weight loss have produced inconsistent, small signals that do not survive correction for cell-composition changes and have not been replicated in randomised GLP-1 trials. GLP-1 agonists are therefore best described as modifiers of the metabolic-inflammatory component of aging, not as broad geroprotectors targeting the hallmark set defined by López-Otín et al.

4.6. Liver, Addiction, and Other Emerging Signals — Early Human

Phase 2 data in metabolic dysfunction-associated steatohepatitis (MASH) show histological improvement in steatohepatitis and liver enzymes with semaglutide and tirzepatide, with phase 3 outcomes pending. Observational and small interventional signals for reduced alcohol intake, smoking, and compulsive behaviours via central reward circuits (nucleus accumbens, ventral tegmental area) are biologically plausible given GLP-1 action on mesolimbic dopamine signalling, but randomised addiction endpoints are lacking and should be considered preliminary.

5. Do GLP-1 Agonists Extend Lifespan? A Realistic Assessment

For an obese 60-year-old with established cardiovascular disease, SELECT implies additional years of life expectancy through prevented myocardial infarction and stroke — modelling studies project on the order of 1-3 years at the group level, varying sharply with baseline risk and adherence. FLOW extends this logic to kidney failure, another lethal trajectory that truncates lifespan. This is genuine, demographically meaningful life extension, but it is disease-specific and indirect: the drug suppresses the deadliest complications of the metabolic syndrome rather than slowing aging globally.

Three distinctions are essential:

• Disease treatment versus aging modification. No trial has shown that GLP-1 therapy slows a validated primary aging endpoint in healthy, lean, normoglycaemic individuals, extends maximum lifespan in mammals, or persistently decelerates epigenetic aging independent of weight change. The geroprotection claim is therefore not confirmed.
• Healthspan versus lifespan. Even where lifespan gains are real, they accrue via reduced disability — fewer cardiovascular events, less progression to dialysis, improved mobility — which is the more defensible framing than rejuvenation.
• Surrogate versus hard outcome. Improvements in weight, HbA1c, CRP, or liver fat are not evidence of slower aging. Only trials with mortality or major organ-failure endpoints — SELECT and FLOW — meet the longevity-medicine standard, and both enrolled high-risk populations.

Whether metabolically healthy, normal-weight adults gain lifespan remains unproven and is not supported for prescribing outside trials. The defensible position is that incretin therapy is the most effective currently available pharmacological lever against the cardiometabolic component of aging in high-risk individuals, not a universal longevity drug.

6. Risks, Trade-offs, and the Older Adult

The same biology that produces efficacy creates predictable liabilities, magnified with age and frailty:

• Gastrointestinal intolerance. Nausea (~44%), vomiting (~24%), diarrhoea, constipation, and early satiety affect a substantial minority, usually attenuating over weeks with dose titration but leading to discontinuation in 5-10% in trials.
• Gallbladder disease, pancreatitis, and bowel obstruction. Dose-dependent increases in cholelithiasis and cholecystitis (HR ~1.3-2.0 in meta-analyses), rare acute pancreatitis (~0.2-0.5% vs ~0.1% placebo), and rare ileus/intestinal obstruction have been confirmed in pharmacovigilance and trial adverse-event tables. The absolute excess is small but clinically relevant at population scale.
• Muscle and bone loss. Approximately 25-40% of lost weight is lean mass, with attendant loss of bone mineral density. In older adults with sarcopenic obesity this can threaten strength, gait stability, and fracture risk unless countered by resistance training and adequate protein intake (≥1.0-1.2 g/kg/day where renal function permits) and vitamin D / calcium repletion. No GLP-1 formulation has demonstrated muscle-sparing weight loss without such co-intervention.
• Nutritional and hydration deficits. Marked appetite suppression can produce inadequate micronutrient intake, dehydration, and orthostatic symptoms, particularly during initiation and in the very old.
• Thyroid C-cell and MEN 2 warning. GLP-1 agonists cause dose-dependent C-cell hyperplasia and medullary thyroid tumours in rodents; human relevance is unproven, but personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) remains a contraindication, and the FDA label carries a boxed warning.
• Ophthalmic and other signals. Early worsening of diabetic retinopathy was observed with rapid glycaemic improvement in SUSTAIN-6; subsequent analyses suggest risk is mediated by glycaemic volatility rather than drug class per se. Reports of aspiration during anaesthesia due to delayed gastric emptying have prompted perioperative withholding guidance. Neuropsychiatric signals (depression, suicidality) have not shown a causal increase in large trials or regulatory reviews to date, but monitoring continues.
• Rebound and chronicity. Weight regain after discontinuation is rapid and predictable, as is return of HbA1c and blood pressure toward baseline. Longevity benefit in SELECT and FLOW therefore implies potentially lifelong therapy, with cumulative cost and supply implications. Cost-effectiveness modelling favours high-risk groups and is sensitive to drug price and adherence assumptions.

7. Clinical Positioning Today

Regulatory approvals cover type 2 diabetes (glycaemic control) and overweight/obesity (chronic weight management) with defined BMI thresholds, and, following SELECT, cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease (FDA expanded label 2024 for semaglutide 2.4 mg). Kidney indications are under review following FLOW. No major regulator has approved any GLP-1 agonist for «aging,» «longevity,» or «healthspan» as an indication, and no guideline endorses prescribing to lean, metabolically healthy individuals for lifespan extension.

In practice, the highest benefit-to-risk ratio is in: (a) adults with obesity and established atherosclerotic disease or multiple cardiometabolic risk factors; (b) adults with type 2 diabetes and chronic kidney disease with albuminuria; and (c) adults with severe obesity where 10-20% weight loss meaningfully reduces mechanical and metabolic disability. Candidates require screening for contraindications, counselling on gastrointestinal effects and the need for concurrent resistance exercise and protein sufficiency, and a plan for long-term continuity. Deprescribing should be considered where intolerance persists, lean mass loss dominates, or goals of care shift toward palliation.

The longevity-clinic model — prescribing semaglutide or tirzepatide to healthy, normal-weight individuals on the premise of proven geroprotection — runs ahead of the evidence. It exposes recipients to the full risk set described above without the demonstrable hard-outcome gain that justifies chronic therapy in high-risk groups and without data that epigenetic or functional aging is meaningfully altered.

8. Open Questions and What Would Change the Assessment

• Non-diabetic kidney and liver outcome trials. Will renal benefit generalise beyond diabetic CKD, and will MASH histological improvements translate into fewer liver-related events? Ongoing phase 3 readouts will determine whether the longevity signal broadens from two organs to three.
• Cardiovascular outcomes with tirzepatide and oral semaglutide. SURMOUNT-CVO and SOUL will test whether dual agonism or oral delivery reproduces or exceeds the SELECT effect size with different tolerability and adherence profiles.
• Direct aging-biomarker trials. Randomised studies with primary endpoints of epigenetic clock change, proteomic aging signatures, or functional capacity (VO₂ max, gait speed, muscle strength) in weight-stable or lean cohorts — not just kilogram loss — are required to test geroprotection claims. None with GLP-1 monotherapy has yet met this design.
• Muscle-sparing weight loss. Combination approaches pairing incretins with resistance protocols, higher protein targets, or myostatin/activin-axis inhibitors are under investigation to address the sarcopenia liability that most limits use in older adults.
• Durability after discontinuation. Intermittent, maintenance, or lower-dose regimens that preserve cardiometabolic benefit with fewer adverse effects and lower cost would materially alter the population-health calculus but remain unproven.

9. Future Directions

The class is moving rapidly from single-pathway agonism to polypharmacy in one molecule — dual GIP/GLP-1 (tirzepatide), triple GIP/GCG/GLP-1 (retatrutide), and GLP-1/amylin co-formulations (e.g., cagrilintide + semaglutide, CagriSema) — each aiming for greater weight loss or more selective fat-mass reduction. Oral non-peptide GLP-1 agonists and once-monthly injectables seek to improve adherence. For longevity medicine the more important innovations are not additional kilograms lost but trial architectures that measure what matters to aging: randomised studies in older adults stratified by frailty and muscle mass, with co-primary endpoints of hard organ events and preserved physical function, and with systematic capture of lean mass, bone density, and nutrient status. Without such designs the field risks optimising a surrogate (weight) while eroding a determinant of independent aging (muscle and skeletal integrity).

10. Conclusion

GLP-1 receptor agonists are not elixirs of youth and have not been shown to slow biological aging itself. They are, however, the first widely available pharmacotherapy proven in large randomised trials to reduce the major lethal complications of the metabolic syndrome — myocardial infarction, stroke, cardiovascular death, and progression of diabetic kidney disease — in populations whose age-related mortality is dominated by those complications. Used judiciously, with attention to muscle and bone preservation, nutritional sufficiency, and the expectation of chronic therapy, they represent the strongest currently available pharmacological contribution to extending healthy life expectancy while geroscience pursues deeper interventions into the aging process. The negative EVOKE results are a useful guardrail: longevity medicine should follow the hard outcomes, not the mechanistic narrative.

Recent Developments (2025-2026)

Kidney outcomes (FLOW, 2024). In 3,533 patients with type 2 diabetes and chronic kidney disease, weekly semaglutide 1.0 mg reduced the primary composite of kidney failure, ≥50% eGFR decline, or kidney or cardiovascular death by 24% (HR 0.76) and all-cause mortality by 20%, with the trial stopped early for efficacy — extending the longevity-relevant benefit of GLP-1 therapy from heart to kidney in diabetic CKD.

Alzheimer’s setback (EVOKE / EVOKE+, 2025). Two phase 3 trials in 3,808 patients with early symptomatic Alzheimer’s randomised to oral semaglutide 14 mg daily versus placebo did not slow decline on CDR-SB at 156 weeks, despite effects on certain Alzheimer’s plasma biomarkers; extension phases were discontinued. The result narrows the longevity-medicine claim for incretins to cardiometabolic and renal protection and should temper any presentation of GLP-1 drugs as cognitive rejuvenation agents.

1. Perkovic V. et al. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW).” NEJM, 2024; 391: 109-121. DOI: 10.1056/NEJMoa2403347
2. Alzheimer Europe: EVOKE / EVOKE+ results (CTAD 2025) — No effect of oral semaglutide on Alzheimer progression; extension discontinued. Alzheimer Europe summary
3. ClinicalTrials.gov: EVOKE (NCT04777396) and EVOKE+ (NCT04777409) — Study records for oral semaglutide in early Alzheimer disease. ClinicalTrials.gov

Sources and Key Research Centers

1. Wilding J.P.H. et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” NEJM, 2021; 384: 989-1002. DOI: 10.1056/NEJMoa2032183
2. Jastreboff A.M. et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” NEJM, 2022; 387: 205-216. DOI: 10.1056/NEJMoa2206038
3. Lincoff A.M. et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).” NEJM, 2023; 389: 2221-2232. DOI: 10.1056/NEJMoa2307563
4. Perkovic V. et al. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW).” NEJM, 2024; 391: 109-121. DOI: 10.1056/NEJMoa2403347
5. Marso S.P. et al. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER).” NEJM, 2016; 375: 311-322. DOI: 10.1056/NEJMoa1603827
6. Marso S.P. et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).” NEJM, 2016; 375: 1834-1844. DOI: 10.1056/NEJMoa1607141
7. Gerstein H.C. et al. “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND).” Lancet, 2019; 394: 121-130. DOI: 10.1016/S0140-6736(19)31149-3
8. Drucker D.J., Nauck M.A. “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.” Lancet, 2006; 368: 1696-1705. DOI: 10.1016/S0140-6736(06)69705-5
9. Drucker D.J. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell Metabolism, 2018; 27: 740-756. DOI: 10.1016/j.cmet.2018.03.001
10. López-Otín C. et al. “Hallmarks of aging: An expanding universe.” Cell, 2023; 186: 243-278. DOI: 10.1016/j.cell.2022.11.001
11. U.S. Food and Drug Administration (FDA) — Regulatory reviews, boxed warnings, and 2024 expanded cardiovascular indication for semaglutide 2.4 mg (Wegovy). FDA
12. ClinicalTrials.gov — Ongoing outcome trials: SURMOUNT-CVO, SOUL (oral semaglutide), and studies of retatrutide and CagriSema. ClinicalTrials.gov